David Robert Vincent

Array ( [id] => 15571605 [patent_doc_number] => 10576162 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-03 [patent_title] => Bifunctional polypeptides [patent_app_type] => utility [patent_app_number] => 16/378501 [patent_app_country] => US [patent_app_date] => 2019-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 8871 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16378501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14881651 [patent_doc_number] => 10420846 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Bifunctional polypeptides [patent_app_type] => utility [patent_app_number] => 16/378505 [patent_app_country] => US [patent_app_date] => 2019-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 8873 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16378505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454559 [patent_doc_number] => 20200040104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/377809 [patent_app_country] => US [patent_app_date] => 2019-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16377809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582869 [patent_doc_number] => 20210017271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => Neutralization of Human Cytokines with Membrane-Bound Anti-Cytokine Non-Signaling Binders Expressed in Immune Cells [patent_app_type] => utility [patent_app_number] => 17/040387 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14566939 [patent_doc_number] => 20190211076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/362551 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206337 [patent_doc_number] => 20190365855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => USE OF RECOMBINANT LYMPHOCYTE ACTIVATION GENE-3 AS A COMPANION THERAPEUTIC FOR PATIENTS AT RISK FOR CARDIOVASCULAR DISEASE AND OTHER CHRONIC INFLAMMATORY DISEASES [patent_app_type] => utility [patent_app_number] => 16/360610 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16360610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17800176 [patent_doc_number] => 11414457 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Immunogenic WT-1 peptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/359897 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 23 [patent_no_of_words] => 29193 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16359897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836269 [patent_doc_number] => 20190276535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/357541 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16357541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14535175 [patent_doc_number] => 20190203209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => Method of Modulating Fibroblast Accumulation or Collagen Deposition [patent_app_type] => utility [patent_app_number] => 16/356807 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15668893 [patent_doc_number] => 10598669 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Isolating cells expressing secreted proteins [patent_app_type] => utility [patent_app_number] => 16/352154 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 59 [patent_no_of_words] => 15860 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363631 [patent_doc_number] => 20200017580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/284798 [patent_app_country] => US [patent_app_date] => 2019-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16284798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496355 [patent_doc_number] => 20200048366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/282949 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844945 [patent_doc_number] => 11434298 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Antibodies to CD70 [patent_app_type] => utility [patent_app_number] => 16/278522 [patent_app_country] => US [patent_app_date] => 2019-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 24 [patent_no_of_words] => 42473 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16278522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398841 [patent_doc_number] => 20200339699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => FULLY HUMANIZED ANTI-B CELL MATURATION ANTIGEN (BCMA) SINGLE-CHAIN ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/759956 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578551 [patent_doc_number] => 20190216884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY [patent_app_type] => utility [patent_app_number] => 16/263124 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743975 [patent_doc_number] => 20190255161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/263913 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309091 [patent_doc_number] => 10519236 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Antibodies specific to delta 1 chain of T cell receptor [patent_app_type] => utility [patent_app_number] => 16/255769 [patent_app_country] => US [patent_app_date] => 2019-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 64 [patent_no_of_words] => 51743 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16255769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372477 [patent_doc_number] => 12479901 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => T-cell receptor [patent_app_type] => utility [patent_app_number] => 16/961409 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 27 [patent_no_of_words] => 8563 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1026 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638092 [patent_doc_number] => 12168693 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Combining CD27 agonists and immune checkpoint inhibition for immune stimulation [patent_app_type] => utility [patent_app_number] => 16/249404 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 15581 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673112 [patent_doc_number] => 20210061875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 16/958539 [patent_app_country] => US [patent_app_date] => 2018-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958539 [rel_patent_id] =>[rel_patent_doc_number] =>)